Home > Healthcare > Drug Device Combination > Therapeutic Systems > Surgical Hemostats Market

Surgical Hemostats Market Share

Report ID: GMI7748
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Surgical Hemostats Market Share

The surgical hemostats industry is consolidated, with key players including Medtronic Plc, Ethicon, Inc. (Johnson & Johnson), Baxter International Inc., Teleflex Corporation, Pfizer, Inc., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in September 2022, Medtronic plc announced U.S. FDA clearance for its Nexpowder endoscopic hemostasis system. This system is developed by Nextbiomedical CO., LTD and distributed by Medtronic. Additionally, this system is designed to address upper gastrointestinal nonvariceal bleeding, a common medical issue that accounts for a significant portion of acute gastrointestinal (GI) bleeding cases. Such product approvals help companies to strengthen its product offerings and generate significant revenue.

Surgical Hemostats Market Companies

Some of the eminent market participants operating in the surgical hemostats industry include:

Becton, Dickinson and Company
Medtronic plc
Teleflex Corporation
Baxter International Inc.
B. Braun Melsungen AG
Pfizer, Inc.
Ethicon, Inc. (Johnson & Johnson)
Stryker Corporation
CuraMedical BV
Gelita Medical GmbH
Integra LifeSciences
Marine Polymer Technologies, Inc
Hemostasis LLC

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for surgical hemostats was valued at USD 3.3 billion in 2023 and is estimated to reach USD 5.3 billion by 2032 as they are used to promote hemostasis, which is the process of stopping or controlling bleeding.

Oxidized regenerated cellulose-based segment held 19.9% revenue share in the surgical hemostats industry in 2023 and will grow significantly through 2032 due to its application in cardiac, orthopedic, and general surgeries, combined with a favorable safety profile.

U.S. surgical hemostats market accounted for USD 1.1 billion in 2023 and is predicted to witness substantial market growth through 2032 due to the advanced healthcare infrastructure, a high incidence of chronic diseases, and continuous technological innovations.

Becton, Dickinson and Company, Medtronic plc, Teleflex Corporation, Baxter International Inc., B. Braun Melsungen AG, Pfizer, Inc., Ethicon, Inc. (Johnson & Johnson), Stryker Corporation, CuraMedical BV, Gelita Medical GmbH, Integra LifeSciences, Marine Polymer Technologies, Inc, and Hemostasis LLC.